Literature DB >> 8254775

Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.

A D Smith1, D A Resnick, A Zhang, S C Geisler, E Arnold, G F Arnold.   

Abstract

Random systematic mutagenesis was used to generate a library of human rhinovirus 14 chimeras that each display a segment from the V3 loop of human immunodeficiency virus type 1. The sequence XXIGPGRAXX, where X could be any of the 20 amino acids, was inserted at the neutralizing immunogenic site II of human rhinovirus 14 between VP2 residues 159 and 160. Twenty-five unique chimeric viruses were isolated, and the identity of their randomized residues was determined. A nonrandom amino acid distribution that may reflect structural requirements for viability was observed at the randomized positions. Fifteen of 25 chimeras were neutralized by one or more of a panel of four anti-human immunodeficiency virus type 1 V3 loop antibody preparations, indicating that antigenicity had been successfully transplanted. Libraries of chimeric viruses produced by using the techniques described may be a source of vaccines and other immunotherapeutic reagents. The random systematic mutagenesis methodology described should be generally useful for the rapid transplantation of foreign sequences into viral coat and other proteins to produce libraries containing members with the desired properties.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254775      PMCID: PMC236325     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.

Authors:  S M Lemon; W Barclay; M Ferguson; P Murphy; L Jing; K Burke; D Wood; K Katrak; D Sangar; P D Minor
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

3.  Modelling of poliovirus. HIV-1 antigen chimaeras.

Authors:  M J Crabbe; D J Evans; J W Almond
Journal:  FEBS Lett       Date:  1990-10-01       Impact factor: 4.124

4.  Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.

Authors:  B Y Reimann; R Zell; R Kandolf
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.

Authors:  C Y Wang; D J Looney; M L Li; A M Walfield; J Ye; B Hosein; J P Tam; F Wong-Staal
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

6.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

7.  Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs.

Authors:  J D Kitson; K L Burke; L A Pullen; G J Belsham; J W Almond
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  Construction and characterization of a poliovirus/rhinovirus antigenic hybrid.

Authors:  R Altmeyer; A D Murdin; J J Harber; E Wimmer
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

9.  Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J F Dedieu; J Ronco; S van der Werf; J M Hogle; Y Henin; M Girard
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  T Ohno; M Terada; Y Yoneda; K W Shea; R F Chambers; D M Stroka; M Nakamura; D W Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more
  13 in total

Review 1.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

2.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

3.  Attenuated Mengo virus: a new vector for live recombinant vaccines.

Authors:  R Altmeyer; M Girard; S van der Werf; V Mimic; L Seigneur; M F Saron
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Authors:  A D Smith; S C Geisler; A A Chen; D A Resnick; B M Roy; P J Lewi; E Arnold; G F Arnold
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Authors:  Mauro Lapelosa; Gail Ferstandig Arnold; Emilio Gallicchio; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

6.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

7.  Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120.

Authors:  R Altmeyer; N Escriou; M Girard; A Palmenberg; S van der Werf
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.

Authors:  M Mamounas; D J Looney; R Talbott; F Wong-Staal
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.

Authors:  D A Resnick; A D Smith; S C Gesiler; A Zhang; E Arnold; G F Arnold
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.

Authors:  Qiana L Matthews; Aiman Fatima; Yizhe Tang; Brian A Perry; Yuko Tsuruta; Svetlana Komarova; Laura Timares; Chunxia Zhao; Natalia Makarova; Anton V Borovjagin; Phoebe L Stewart; Hongju Wu; Jerry L Blackwell; David T Curiel
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.